333 related articles for article (PubMed ID: 28334439)
61. The clinical significance of KIT mutations in melanoma: a meta-analysis.
Gong HZ; Zheng HY; Li J
Melanoma Res; 2018 Aug; 28(4):259-270. PubMed ID: 29746316
[TBL] [Abstract][Full Text] [Related]
62. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
63. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
64. C-kit-mutated melanomas: the Chinese experience.
Si L; Guo J
Curr Opin Oncol; 2013 Mar; 25(2):160-5. PubMed ID: 23299198
[TBL] [Abstract][Full Text] [Related]
65. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
66. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
67. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
68. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.
Gremel G; Lee RJ; Girotti MR; Mandal AK; Valpione S; Garner G; Ayub M; Wood S; Rothwell DG; Fusi A; Wallace A; Brady G; Dive C; Dhomen N; Lorigan P; Marais R
Ann Oncol; 2016 Oct; 27(10):1959-65. PubMed ID: 27502704
[TBL] [Abstract][Full Text] [Related]
69. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
Torres-Cabala CA; Wang WL; Trent J; Yang D; Chen S; Galbincea J; Kim KB; Woodman S; Davies M; Plaza JA; Nash JW; Prieto VG; Lazar AJ; Ivan D
Mod Pathol; 2009 Nov; 22(11):1446-56. PubMed ID: 19718013
[TBL] [Abstract][Full Text] [Related]
70. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.
Wei X; Mao L; Chi Z; Sheng X; Cui C; Kong Y; Dai J; Wang X; Li S; Tang B; Lian B; Yan X; Bai X; Zhou L; Guo J; Si L
Oncol Res; 2019 Mar; 27(4):495-501. PubMed ID: 30075827
[TBL] [Abstract][Full Text] [Related]
71. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
72. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
73. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
[TBL] [Abstract][Full Text] [Related]
74. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.
Posch C; Moslehi H; Sanlorenzo M; Green G; Vujic I; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2016 Jul; 7(29):45916-45925. PubMed ID: 27322141
[TBL] [Abstract][Full Text] [Related]
75. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
76. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
Lassman AB; Pugh SL; Gilbert MR; Aldape KD; Geinoz S; Beumer JH; Christner SM; Komaki R; DeAngelis LM; Gaur R; Youssef E; Wagner H; Won M; Mehta MP
Neuro Oncol; 2015 Jul; 17(7):992-8. PubMed ID: 25758746
[TBL] [Abstract][Full Text] [Related]
77. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
[TBL] [Abstract][Full Text] [Related]
78. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
79. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
80. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
